As of 30 Sep 2025, 496 institutional investors reported holding 60,646,839 shares of Jazz Pharmaceuticals plc - SHS USD (JAZZ).
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 988,943 | $168,120,054 | -$58,562,873 | $170.00 | 59 |
| 2025 Q3 | 60,646,839 | $7,990,711,487 | -$156,371,998 | $131.80 | 496 |
| 2025 Q2 | 61,824,515 | $6,561,677,298 | +$172,218,482 | $106.12 | 497 |
| 2025 Q1 | 59,973,813 | $7,442,798,617 | +$115,230,167 | $124.15 | 545 |
| 2024 Q4 | 59,002,163 | $7,265,494,814 | +$147,830,867 | $123.15 | 502 |
| 2024 Q3 | 57,597,455 | $6,415,433,594 | +$58,344,093 | $111.41 | 469 |
| 2024 Q2 | 57,463,700 | $6,133,341,626 | -$38,433,148 | $106.73 | 451 |
| 2024 Q1 | 57,711,183 | $6,947,614,300 | +$89,820,559 | $120.42 | 475 |
| 2023 Q4 | 57,060,984 | $7,017,863,210 | -$56,981,989 | $123.00 | 491 |
| 2023 Q3 | 56,530,271 | $7,318,098,320 | -$17,277,114 | $129.44 | 482 |
| 2023 Q2 | 56,728,151 | $7,039,068,770 | -$22,114,573 | $123.97 | 465 |
| 2023 Q1 | 56,681,319 | $8,292,329,555 | +$108,158,178 | $146.33 | 462 |
| 2022 Q4 | 56,178,304 | $8,948,272,058 | -$100,056,709 | $159.31 | 475 |
| 2022 Q3 | 56,928,016 | $7,590,657,250 | -$96,379,512 | $133.29 | 443 |
| 2022 Q2 | 57,260,089 | $8,932,716,610 | +$138,065,500 | $156.01 | 448 |
| 2022 Q1 | 56,748,008 | $8,837,789,303 | -$111,358,494 | $155.67 | 437 |
| 2021 Q4 | 57,664,502 | $7,350,056,970 | +$21,422,030 | $127.40 | 422 |
| 2021 Q3 | 56,879,540 | $7,407,482,783 | -$119,725,201 | $130.21 | 422 |
| 2021 Q2 | 57,178,368 | $10,156,395,395 | +$780,868,772 | $177.64 | 481 |
| 2021 Q1 | 53,127,709 | $8,729,942,643 | +$29,540,811 | $164.37 | 435 |
| 2020 Q4 | 52,654,654 | $8,685,222,791 | -$294,935,573 | $165.05 | 428 |
| 2020 Q3 | 54,543,371 | $7,767,396,418 | +$369,110,226 | $142.59 | 382 |
| 2020 Q2 | 52,094,206 | $5,741,576,836 | +$270,141,092 | $110.34 | 376 |
| 2020 Q1 | 49,800,360 | $4,968,187,513 | -$262,951,825 | $99.74 | 397 |
| 2019 Q4 | 51,855,668 | $7,738,313,733 | +$162,667,912 | $149.28 | 436 |
| 2019 Q3 | 50,956,459 | $6,527,263,115 | +$97,208,216 | $128.14 | 397 |
| 2019 Q2 | 50,088,303 | $7,125,707,525 | +$206,804,403 | $142.56 | 407 |
| 2019 Q1 | 51,378,205 | $7,336,806,884 | -$212,277,925 | $142.95 | 415 |
| 2018 Q4 | 52,922,692 | $6,549,889,371 | -$427,140,677 | $123.96 | 409 |
| 2018 Q3 | 55,400,378 | $9,303,697,145 | -$146,566,478 | $168.13 | 397 |
| 2018 Q2 | 56,183,461 | $9,670,926,964 | +$435,954,554 | $172.30 | 373 |
| 2018 Q1 | 53,679,721 | $8,093,065,376 | -$76,065,361 | $150.99 | 320 |
| 2017 Q4 | 54,247,348 | $7,295,659,971 | -$66,672,908 | $134.65 | 319 |
| 2017 Q3 | 54,642,574 | $7,995,262,702 | +$210,111,108 | $146.25 | 299 |
| 2017 Q2 | 53,141,372 | $8,263,546,157 | +$374,758,650 | $155.50 | 314 |
| 2017 Q1 | 52,283,523 | $7,587,950,162 | +$512,523,733 | $145.13 | 302 |
| 2016 Q4 | 52,085,929 | $5,676,848,580 | -$158,899,374 | $109.03 | 287 |
| 2016 Q3 | 53,391,287 | $6,483,323,799 | -$52,478,840 | $121.48 | 317 |
| 2016 Q2 | 53,886,553 | $7,614,644,976 | -$43,527,577 | $141.31 | 354 |
| 2016 Q1 | 54,554,481 | $7,120,724,289 | -$230,482,851 | $130.55 | 330 |
| 2015 Q4 | 56,253,036 | $7,906,867,974 | -$16,787,687 | $140.56 | 338 |
| 2015 Q3 | 56,363,725 | $7,485,153,388 | +$25,070,936 | $132.81 | 350 |
| 2015 Q2 | 55,981,344 | $9,856,454,549 | +$619,952,018 | $176.07 | 367 |
| 2015 Q1 | 52,457,739 | $9,064,673,642 | -$333,658,314 | $172.79 | 352 |
| 2014 Q4 | 54,301,590 | $8,892,764,640 | +$176,201,808 | $163.73 | 351 |
| 2014 Q3 | 53,225,671 | $8,544,993,638 | +$384,771,818 | $160.56 | 320 |
| 2014 Q2 | 50,728,244 | $7,457,848,518 | +$45,563,248 | $147.01 | 299 |
| 2014 Q1 | 50,472,408 | $6,997,331,929 | +$318,974,123 | $138.68 | 310 |